Icon

ZILBRYSQ (NDA216834)- (EQ 16.6MG BASE/0.416ML (EQ 16.6MG BASE/0.416ML),EQ 23MG BASE/0.574ML (EQ 23MG BASE/0.574ML),EQ 32.4MG BASE/0.81ML (EQ 32.4 BASE/0.81ML))

ZILUCOPLAN SODIUM UCB INC
EQ 16.6MG BASE/0.416ML (EQ 16.6MG BASE/0.416ML),EQ 23MG BASE/0.574ML (EQ 23MG BASE/0.574ML),EQ 32.4MG BASE/0.81ML (EQ 32.4 BASE/0.81ML)
No No
2035-Jun-12 2028-Oct-17
None None
None No
ZILBRYSQ is a complement inhibitor indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are antiacetylcholine receptor (AChR) antibody positive.
0 0 0
Total Other Developers None
Drugs with Suitability No
EQ 16.6MG BASE/0.416ML (EQ 16.6MG BASE/0.416ML) ** ** - - -
EQ 23MG BASE/0.574ML (EQ 23MG BASE/0.574ML) ** ** - - -
EQ 32.4MG BASE/0.81ML (EQ 32.4 BASE/0.81ML) ** ** - - -
NDA Sales Available Total Generic Sales Available
No 0
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.